Back to search
FDAFDA · Food and drugs·Recall number D-1543-2022

Neoral soft gelatin capsules (cyclosporine capsules, USP) Modified, 25 mg, Rx Only, 30 Soft Gelatin Capsules per carton, Mfg by: Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, NDC # 0078-0246-15.

Published October 5, 2022 · Recall initiated: September 16, 2022

Summary

FDA records drug Class II recall D-1543-2022, published October 5, 2022 and initiated September 16, 2022. Recalling firm: Novartis Pharmaceuticals Corporation; Status: Terminated; Reported quantity: 132,999 cartons; Lot: Lot # APCD162, Exp. 01/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP deviations: Out of specification results obtained during routine stability testing for ethanol content.

What to do

Voluntary: Firm initiated · Letter

Get an email if NEORAL has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
NEORAL
Manufacturer
Novartis Pharmaceuticals Corporation
Distributor
Nationwide and Puerto Rico
Lot
Lot # APCD162, Exp. 01/2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Neoral soft gelatin capsules (cyclosporine capsules, USP) Modified, 25 mg, Rx Only, 30 Soft Gelatin Capsules per carton, Mfg by: Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, NDC # 0078-0246-15. recalled?

Yes. FDA published recall D-1543-2022 on October 5, 2022. Reported hazard: CGMP deviations: Out of specification results obtained during routine stability testing for ethanol content.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: NEORAL.